Policy Summit ASGCT Publications
The 2020 Policy Summit will cover regulatory and government relations, market access, and ethical issues over 2.5 days, September 23-25. Find agendas, speaker information, and sponsorship opportunities here.
Learn More
Gene and cell therapy will have a financial impact on patients, providers, and payers. ASGCT is committed to understanding that impact and educating decision-makers engaged in developing policies that influence patient access to treatments.
The benefits gene and cell therapy deliver to patients are cultivated and sustained through federally funded research programs and policies that support investment. ASGCT supports the effort to bring new therapies from the lab to the public.
As the promise of gene and cell therapy becomes a reality, ASGCT is leading the conversation among policy makers by encouraging open and thorough discussion. The Society is intent on yielding thoughtful and well-informed health policies.
Learn about recent legislative issues that ASGCT is monitoring or taking action on.
Read about regulatory changes that effect the field of gene and cell therapy.
To strengthen ASGCT’s advocacy efforts and its ability to significantly impact policymakers on a larger scale, the Society maintains partnership with coalitions, other professional membership associations, research foundations, and patient advocacy groups.
ASGCT is committed to advancing gene and cell therapy through three primary objectives: defining value, supporting research, and promoting awareness.
Read recent ASGCT publications including the white paper on gene editing and our response to the National Center for Advancing Translational Sciences request for information.
The Government Relations Committee and the Clinical Trials & Regulatory Affairs Committee have both been tracking legislation, working with regulatory bodies, and advocating for the members of ASGCT.
May 12-15, 2021
© 2000-2020 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico